{"text": ["Advanced", "Accelerator", "Applications", "Receives", "FDA", "Approval", "for", "Lutathera\u00ae", "for", "Treatment", "of", "Gastroenteropancreatic", "Neuroendocrine", "Tumors"], "created_at": "2018-01-26 18:03:01"}
{"text": ["Stocks", "With", "Rising", "Relative", "Strength:", "Novartis"], "created_at": "2018-01-26 16:01:07"}
{"text": ["Stocks", "With", "Rising", "Relative", "Strength:", "Novartis"], "created_at": "2018-01-26 16:01:07"}
{"text": ["Novartis", "Gets", "Spark", "Therapeutics'", "Luxterna", "License", "Outside", "US"], "created_at": "2018-01-26 15:59:59"}
{"text": ["Novartis", "Gets", "Spark", "Therapeutics'", "Luxterna", "License", "Outside", "US"], "created_at": "2018-01-26 15:59:59"}
{"text": ["Anoro", "Ellipta", "May", "Boost", "GlaxoSmithKline\u2019s", "Respiratory", "Franchise", "Revenues"], "created_at": "2018-01-26 15:33:41"}
{"text": ["Novartis", "Gets", "Spark", "Therapeutics&apos;", "Luxterna", "License", "Outside", "US"], "created_at": "2018-01-26 14:20:02"}
{"text": ["GlaxoSmithKline", "Is", "Focused", "on", "Maintaining", "Leadership", "in", "This", "Segment"], "created_at": "2018-01-26 14:04:39"}
{"text": ["What", "to", "Expect", "for", "Novartis\u2019s", "Subsidiary", "Alcon", "in", "2018"], "created_at": "2018-01-26 14:00:15"}
{"text": ["GlaxoSmithKline", "Has", "Developed", "a", "Broad", "Respiratory", "Portfolio"], "created_at": "2018-01-26 12:37:07"}
{"text": ["Taking", "Stock", "of", "Radius", "Health\u2019s", "Financial", "Performance"], "created_at": "2018-01-26 12:34:29"}
{"text": ["How", "Is", "Novartis\u2019s", "Subsidiary", "Sandoz", "Positioned", "for", "2018?"], "created_at": "2018-01-26 12:30:15"}
{"text": ["The", "Swiss", "Stock", "Market", "Recovered", "Some", "Lost", "Ground"], "created_at": "2018-01-26 12:28:00"}
{"text": ["The", "Swiss", "Stock", "Market", "Recovered", "Some", "Lost", "Ground"], "created_at": "2018-01-26 12:28:00"}
